Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NorMig dual therapy trial in chronic migraine
2024-517981-40-00Phase 3Authorised
- Sponsor
- Oslo University Hospital
- Start
- Jun 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of erenumab, fremanezumab, galcanezumab and onabotulinumtoxinA in chronic migraine (2 arms), sponsored by Oslo University Hospital. Primary endpoint: Reduction of monthly migraine days over 12 weeks. Planned start Jun 2025; status: authorised.
02
Drugs
erenumabfremanezumabgalcanezumabonabotulinumtoxinA
03
Conditions
chronic migraine
Beyond the preview
Go deeper on 2024-517981-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517981-40-00.